SCHEMBL15051624

SCHEMBL15051624

NC(=O)c1cn(-c2ccnc(Cl)c2)nc1-c1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
GALR3 O60755 1/20 0.45
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
CA9 Q16790 3/20 0.41
PKM P14618 1/20 0.41
PARP1 P09874 2/20 0.40
PARP2 Q9UGN5 1/20 0.40
PARP3 Q9Y6F1 1/20 0.40
JAK2 O60674 1/20 0.40
SCN9A Q15858 4/20 0.39
IKBKB O14920 1/20 0.38
ADRA1D P25100 2/20 0.38
HSD17B10 Q99714 1/20 0.38
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15051894 0.89 ALDH1A1 (0.47) KDM4EALDH1A1HSD17B10
SCHEMBL15051508 0.88 SCN9A (0.37) KDM4EALDH1A1SCN9AHSD17B10
SCHEMBL15051300 0.85 MAPT (0.51) KDM4EALDH1A1CA12CA1CA2
SCHEMBL15051533 0.84 ALDH1A1 (0.39) KDM4EALDH1A1GALR3HSD17B10
SCHEMBL15051183 0.84 JAK2 (0.43) KDM4EALDH1A1GALR3CA12CA1
SCHEMBL15050714 0.82 IKBKB (0.39) KDM4EPARP1PARP2PARP3JAK2
SCHEMBL15072529 0.79 ALDH1A1 (0.35) KDM4EALDH1A1
SCHEMBL15051665 0.79 PTGS2 (0.46) KDM4EALDH1A1PKM
SCHEMBL15050838 0.79 TUBB4A (0.44) PARP1JAK2DPP4DPP8MAPK1
SCHEMBL15058079 0.78 SCN9A (0.37) KDM4EALDH1A1GALR3PKMSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 KDM4E 1614/4885ALDH1A1 2884/4885GALR3 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.